IAMI

Notable and CicloMed Initiate Phase 1B/2A Clinical Trial of Fosciclopirox in Acute Myelogenous Leukemia Under Co-Development Agreement

Retrieved on: 
Wednesday, December 1, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Patient, CEO, University, Safety, Capital, University of Kansas Medical Center, PK, Population, Cytarabine, Partnership, AML, Cancer, Capital Group Companies, Clinical trial, Labs, Solution, National Cancer Institute, Program, Institute, Builder, Organization, First Round Capital, IAMI, Founders Fund, Y Combinator, Lightspeed Venture Partners, Multimedia, Drug development, Pharmaceutical industry, Fosciclopirox, CicloMed LLC, Notable, FOSCICLOPIROX, CICLOMED LLC, NOTABLE

Notable Labs, Inc. (Notable), a clinical-stage predictive precision therapeutics company and CicloMed LLC (CicloMed), a developmental-stage pharmaceutical company have initiated a Phase 1B/2A clinical trial of fosciclopirox in patients with refractory acute myelogenous leukemia (AML) under the terms of a co-development agreement.

Key Points: 
  • Notable Labs, Inc. (Notable), a clinical-stage predictive precision therapeutics company and CicloMed LLC (CicloMed), a developmental-stage pharmaceutical company have initiated a Phase 1B/2A clinical trial of fosciclopirox in patients with refractory acute myelogenous leukemia (AML) under the terms of a co-development agreement.
  • Fosciclopirox is a strategically and deliberately selected program, as it has already performed well on our predictive precision medicines platform.
  • The encouraging results from this work led to our co-development agreement and the initiation of our on-going clinical trial.
  • Under the terms of the co-development agreement, CicloMed holds the primary responsibility for executing clinical trial operations while Notable is primarily focused on optimizing Notables predictive precision medicine platform.

UltraSight Collaboration with GE Healthcare will bring Wireless Cardiac Point of Care Ultrasound to Space

Retrieved on: 
Thursday, September 30, 2021
Newton, GE Healthcare, News, Telehealth, PDR, International Space Station, ISS, Diagnosis, Health, Moon, Atlantis, Patient, Scientific research on the International Space Station, Thomas Edison, Emergency, MD, AI, LinkedIn, Echocardiography, TEL, Family, Israel Space Agency, Twitter, CEO, Communication, International, Design review (U.S. government), General manager, Technology, Axiom, POCUS, IAMI, Artemis, Machine learning, Ecosystem, Cardiology, GE, Medical device, Medical imaging

We are excited to collaborate with GE Healthcare and lead a new wave of medical innovation in space."

Key Points: 
  • We are excited to collaborate with GE Healthcare and lead a new wave of medical innovation in space."
  • In May 2021, UltraSight was selected by the Israel Space Agency to conduct the cardiac study aboard the 'Rakia' space mission.
  • This is not the first time a GE Healthcare ultrasound device was used in space.
  • The UltraSight automated guidance system and advanced usability features help bring the benefits of cardiac imaging to more healthcare professionals in new care settings, allowing patients access to ultrasound anywhere.